The European Medicines Agency (EMA) Suffers Cyber Attack
BioNTech released a statement on December 9, 2020 that Pfizer and their COVID-19 vaccine documents was “unlawfully accessed” in a breach on the European Medical Agency's (EMA) system. The severity of the attack was not divulged, however the EMA disclosed that they...
FDA Breakthrough Designation Given to ReGelTec
ReGelTec, a medical device company out of Baltimore’s leading medical device HYDRAFIL, has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA). The Breakthrough Device Program was created with intentions to expedite the...
Injection for Treatment of Hereditary Angioedema Released in China
Today (12/8) Takeda announced the approval of the first modern preventative therapy for Hereditary Angioedema, TAHZYRO, for patients 12 and above from China’s National Medical Products Association (NMPA). The disease is chronic and life threatening, and it affects one...
CRISPR Therapeutics & Vertex Pharmaceuticals Present Data on Gene-Editing Therapy for Sickle Cell Disease
The New England Journal of Medicine detailed findings of a sickle cell anemia treatment that showed promising data, marking huge strides in CRISPR technology as well as gene editing. These findings were published on December 5, 2020 and were...
Analysis on Pfizer’s COVID-19 Vaccine Distribution Leaves Many Healthcare Workers Unprotected
Countrywide, hospitals are preparing for the first 3.2 million shipments of Pfizer’s COVID-19 vaccine. The first round of shipments will be distributed to five government agencies before Moderna’s vaccine hits the market. State’s will have final say on...
World Health Organization (WHO) Considers E-Vaccination Certificates
Today (12/3) a World Health Organization (WHO) medical expert divulged the organization’s discussions on an e-vaccination certificate for recovered COVID-19 travelers. The WHO has previously expressed concerns regarding "immunity passports" recommendations,...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com